Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
EUR 50.65
(2.12%)
EUR 50.65
(2.12%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 829.5 Million EUR | 1.44% |
| 2022 | 817.69 Million EUR | 26.06% |
| 2021 | 648.67 Million EUR | 54.46% |
| 2020 | 419.96 Million EUR | 10.14% |
| 2019 | 381.31 Million EUR | 25.76% |
| 2018 | 303.2 Million EUR | 10.0% |
| 2017 | 275.64 Million EUR | 3.95% |
| 2016 | 265.16 Million EUR | 7.79% |
| 2015 | 246 Million EUR | 3.34% |
| 2014 | 238.04 Million EUR | 9.4% |
| 2013 | 217.58 Million EUR | 7.76% |
| 2012 | 201.92 Million EUR | 9.32% |
| 2011 | 184.7 Million EUR | 16.43% |
| 2010 | 158.64 Million EUR | 37.76% |
| 2009 | 115.15 Million EUR | -9.71% |
| 2008 | 127.54 Million EUR | 26.64% |
| 2007 | 100.71 Million EUR | 28.08% |
| 2006 | 78.62 Million EUR | -100.0% |
| 2005 | 7846.54 Billion EUR | 111175.25% |
| 2004 | 7.05 Billion EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 178.16 Million EUR | 17.85% |
| 2024 Q1 | 151.17 Million EUR | -35.57% |
| 2023 FY | 829.5 Million EUR | 1.44% |
| 2023 Q2 | 179.21 Million EUR | -11.12% |
| 2023 Q1 | 201.63 Million EUR | -16.75% |
| 2023 Q4 | 234.63 Million EUR | 9.63% |
| 2023 Q3 | 214.02 Million EUR | 19.43% |
| 2022 Q4 | 242.2 Million EUR | 24.14% |
| 2022 FY | 817.69 Million EUR | 26.06% |
| 2022 Q1 | 205.58 Million EUR | 11.02% |
| 2022 Q2 | 174.81 Million EUR | -14.96% |
| 2022 Q3 | 195.09 Million EUR | 11.6% |
| 2021 Q4 | 185.17 Million EUR | 6.76% |
| 2021 FY | 648.67 Million EUR | 54.46% |
| 2021 Q1 | 130.54 Million EUR | 10.8% |
| 2021 Q2 | 159.5 Million EUR | 22.18% |
| 2021 Q3 | 173.45 Million EUR | 8.74% |
| 2020 Q3 | 111.01 Million EUR | 23.12% |
| 2020 FY | 419.96 Million EUR | 10.14% |
| 2020 Q1 | 100.96 Million EUR | -8.65% |
| 2020 Q2 | 90.16 Million EUR | -10.7% |
| 2020 Q4 | 117.81 Million EUR | 6.13% |
| 2019 Q2 | 95.38 Million EUR | 16.1% |
| 2019 Q4 | 110.53 Million EUR | 18.53% |
| 2019 FY | 381.31 Million EUR | 25.76% |
| 2019 Q1 | 82.15 Million EUR | -2.57% |
| 2019 Q3 | 93.24 Million EUR | -2.24% |
| 2018 Q4 | 84.31 Million EUR | 16.18% |
| 2018 Q3 | 72.57 Million EUR | 2.88% |
| 2018 Q2 | 70.54 Million EUR | -6.9% |
| 2018 Q1 | 75.76 Million EUR | 4.88% |
| 2018 FY | 303.2 Million EUR | 10.0% |
| 2017 FY | 275.64 Million EUR | 3.95% |
| 2017 Q4 | 72.24 Million EUR | 11.74% |
| 2017 Q3 | 64.65 Million EUR | -9.33% |
| 2017 Q2 | 71.29 Million EUR | 5.69% |
| 2017 Q1 | 67.46 Million EUR | -8.48% |
| 2016 Q2 | 68.19 Million EUR | 12.41% |
| 2016 Q1 | 60.66 Million EUR | -11.26% |
| 2016 FY | 265.16 Million EUR | 7.79% |
| 2016 Q3 | 62.59 Million EUR | -8.21% |
| 2016 Q4 | 73.71 Million EUR | 17.77% |
| 2015 Q1 | 60.76 Million EUR | -6.16% |
| 2015 FY | 246 Million EUR | 3.34% |
| 2015 Q4 | 68.36 Million EUR | 21.25% |
| 2015 Q3 | 56.38 Million EUR | -6.79% |
| 2015 Q2 | 60.49 Million EUR | -0.45% |
| 2014 Q4 | 64.75 Million EUR | 13.63% |
| 2014 FY | 238.04 Million EUR | 9.4% |
| 2014 Q1 | 57.62 Million EUR | 1.7% |
| 2014 Q2 | 58.68 Million EUR | 1.83% |
| 2014 Q3 | 56.98 Million EUR | -2.88% |
| 2013 Q4 | 56.66 Million EUR | 10.42% |
| 2013 FY | 217.58 Million EUR | 7.76% |
| 2013 Q1 | 53.78 Million EUR | -44.58% |
| 2013 Q2 | 55.83 Million EUR | 3.82% |
| 2013 Q3 | 51.31 Million EUR | -8.1% |
| 2012 Q4 | 97.04 Million EUR | 99.24% |
| 2012 FY | 201.92 Million EUR | 9.32% |
| 2012 Q1 | 50.94 Million EUR | -42.64% |
| 2012 Q3 | 48.7 Million EUR | -9.68% |
| 2012 Q2 | 53.92 Million EUR | 5.85% |
| 2011 Q4 | 88.81 Million EUR | 100.58% |
| 2011 Q2 | 49.11 Million EUR | 4.99% |
| 2011 Q3 | 44.28 Million EUR | -9.83% |
| 2011 FY | 184.7 Million EUR | 16.43% |
| 2011 Q1 | 46.77 Million EUR | 5.76% |
| 2010 Q3 | 41.69 Million EUR | 5.91% |
| 2010 Q1 | 33.34 Million EUR | 0.0% |
| 2010 Q4 | 44.22 Million EUR | 6.07% |
| 2010 FY | 158.64 Million EUR | 37.76% |
| 2010 Q2 | 39.37 Million EUR | 18.05% |
| 2009 FY | 115.15 Million EUR | -9.71% |
| 2008 FY | 127.54 Million EUR | 26.64% |
| 2007 FY | 100.71 Million EUR | 28.08% |
| 2006 FY | 78.62 Million EUR | -100.0% |
| 2005 FY | 7846.54 Billion EUR | 111175.25% |
| 2004 FY | 7.05 Billion EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Atrys Health, S.A. | 201.56 Million EUR | -311.526% |
| Biotechnologies Assets SA | 3.9 Million EUR | -21123.581% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -5745.065% |
| Pharma Mar, S.A. | 158.15 Million EUR | -424.498% |